BIOLASE STRENGTHENS ITS BOARD – GuruFocus.com


FOOTHILL RANCH, Calif., May 9, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that Kenneth P. YaleDDS, JD was newly elected to its Board of Directors (the “Board”), effective April 28, 2022. Dr. Yale, along with other recently elected Board members, Drs. Kathleen T. O’Loughlin, Carol Gomez Summerhaysand Martha Somermanwill provide insight and support the implementation of the Company’s business plan, which has demonstrated significant growth in recent quarters.

Dr. Yale is currently a member of the Board of Visitors of the University of Maryland School of Dentistryand consultant to the United States Department of Defense (DOD), a position he has held since March 2020. Previously, Dr. Yale served as clinical director at Delta Dental, vice president of clinical solutions and medical director at Aetna, general manager at UnitedHealth Group MSO, and vice president of Matria Healthcare and CorSolutions. He was also Founder and CEO of Advanced Health Solutions, CEO of Health Solutions Network, and Senior Vice President and General Counsel of EduNeering, an internet content company. Dr. Yale also served as chief of staff for the White House Office of Science and Technology and executive director of the White House Domestic Policy Council. Dr. Yale earned a DDS in Dentistry from University of Maryland and a JD in law, science and medicine from Georgetown University. Dr. Yale brings to the Board multidisciplinary clinical, dental and legal expertise with in-depth industry knowledge.

Jonathan T. LordMD, Chairman of the Board of Directors of BIOLASE, said, “Dr. Yale brings more than 20 years of senior management experience in corporations and large healthcare companies, managing teams facing growth and to rapid change, and creating breakthrough innovations in healthcare products and services. His extensive dental experience and industry knowledge complement the diverse makeup of our Board, which is now made up of a majority of dentists. With the help of their clinical expertise, our Board’s newly formed Clinical Committee focuses on aligning our research and development efforts to provide strategic and operational guidance regarding current and planned clinical research and development programs to accelerate the adoption of lasers as the gold standard of care in dentistry We are delighted to welcome Dr. Yale to our Board of Directors and look forward to his contributions as we continue to successfully execute our business plan to achieve our growth objectives.”

About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. BIOLASE products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products offer advanced technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s main products are revolutionary dental laser systems that perform a wide range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries worldwide. The laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™ and laser dentistry, find BIOLASE online at www.biolase.comFacebook at www.facebook.com/biolaseTwitter at www.twitter.com/biolaseincinstagram at www.instagram.com/waterlase_laserdentistryand LinkedIn on www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the planned deployment of new market sales strategies, the Company’s efforts to achieve its goal of becoming EBITDA positive. Forward-looking statements can be identified by the use of words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “seeks”, “estimates”, ” can”, “will”, “should” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations based on a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including, but not limited to, pricing pressures and new product launches, uncertainty as to customer acceptance of new product offerings and market changes, the risks associated with managing the growth of the business, and the other risks and uncertainties that are described, from time to time, in the section “Risk Factors” in BIOLASE’s annual reports filed on Form 10-K with the Securities and Exchange Commission. Except as required by law, BIOLASE assumes no responsibility to revise or update forward-looking statements.

favicon.png?sn=LA49959&sd=2022-05-09 Show original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-strengthens-its-board-of-directors-with-addition-of-seasoned-healthcare-executive-301542269.html

SOURCE BIOLASE, Inc.

Previous Introducing the design firm that brought the Edgy New Gleneagles townhouse to life
Next OnePipe announces the winners of its first writing challenge